Cancer news

Latest news, press releases and blog posts from Cancer Research UK.

Melanoma

Immunotherapy drug made available for some NHS patients with advanced skin cancer after surgery

An immunotherapy drug will be made available to some patients with advanced melanoma skin cancer on the NHS in England.

Immunotherapy drug to be made available for some NHS patients with advanced skin cancer

Some patients with advanced skin cancer will now have access to immunotherapy after surgery on the NHS in England.

Drug combo for advanced skin cancer approved on NHS in England

Patients with a certain type of aggressive skin cancer will now have access to a combination of targeted drugs on the NHS in England.

Blood test could predict skin cancer's return

Scientists have discovered that testing skin cancer patients’ blood for tumour DNA could help predict the chances of an aggressive cancer returning.

Gut bacteria may influence response to cancer immunotherapy

The type of bacteria in the gut of patients with advanced melanoma may influence their response to a certain type immunotherapy, according to new research.

Meet our scientists investigating cancers’ weak spots, showing research ROCKs, and much more

We’d like to introduce the latest bunch of scientists that we’ve given funding to head up their own research teams for the first time.

Immunotherapy and targeted drugs could stop some melanomas from returning

Two clinical trials have found that existing treatments for advanced melanoma could stop the cancer returning in some people with earlier stage disease.

Viruses may boost immunotherapy success

Viruses may improve the success rate of immunotherapy treatments, according to two new studies.

Finding PEACE and remembering my brother Mark – Dave’s story

Dave lost his twin brother to skin cancer at just 28. Here, Dave tells us Mark’s inspiring story through his cancer.

ASCO 2017: 4 ways treatment could change following world’s largest cancer conference

Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.

Pages